Ivosidenib, a mutant IDH1 inhibitor, completed its phase III trials, demonstrating a positive impact on PFS and OS in patients with IDH1 mutant ICC tumor progression despite adequate chemotherapy [41]. The gene discussed is IDH1; the disease is neoplasm.